Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1C | Q14123 | 4/20 | 0.32 |
| ▸ | PDE1A | P54750 | 2/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593295 | 0.80 | TNK2 (0.40) | — | |
| SCHEMBL4370132 | 0.80 | TNK2 (0.40) | — | |
| SCHEMBL16748877 | 0.79 | PDE1C (0.44) | PDE1CPDE1APDE1B | |
| SCHEMBL2327173 | 0.79 | PDE1C (0.50) | PDE1CPDE1APDE1B | |
| SCHEMBL400651 | 0.78 | PDE1C (0.43) | PDE1CPDE1APDE1B | |
| SCHEMBL397564 | 0.77 | PDE1C (0.32) | PDE1CPDE1APDE1B | |
| SCHEMBL18099738 | 0.77 | PDE1C (0.46) | PDE1CPDE1APDE1B | |
| SCHEMBL13962521 | 0.76 | PDE1C (0.47) | PDE1CPDE1APDE1B | |
| SCHEMBL16748881 | 0.76 | TNK2 (0.34) | PDE1CPDE1APDE1B | |
| SCHEMBL2321250 | 0.75 | PDE1C (0.36) | PDE1CPDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-30 | — | — | US | disclosed |
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-30 | — | — | US | disclosed |
| WO-2011060112-A1 | DEUTERATED TYROSINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220595-A1 | Deuterated Tyrosine Kinase Inhibitors | IGF1R, INSR, IRS1 | PDE1C 2504/4885PDE1A 2253/4885PDE1B 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.